About KalVista Pharmaceuticals, Inc.
https://www.kalvista.comKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
CEO
Benjamin L. Palleiko
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2016-11-22 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Showing Top 3 of 105
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Jones Trading
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:6.73M
Value:$102.55M
TANG CAPITAL MANAGEMENT LLC
Shares:5.04M
Value:$76.84M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:5.04M
Value:$76.81M
Summary
Showing Top 3 of 172
About KalVista Pharmaceuticals, Inc.
https://www.kalvista.comKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $13.69M ▲ | $58.51M ▼ | $-49.48M ▲ | -361.39% ▲ | $-0.92 ▲ | $-42.2M ▲ |
| Q1-2026 | $1.43M ▲ | $59.84M ▲ | $-60.1M ▼ | -4.21K% ▼ | $-1.12 ▼ | $-54.16M ▲ |
| Q4-2025 | $0 | $39.14M ▼ | $-52.23M ▼ | 0% | $-1.05 ▼ | $-54.77M ▼ |
| Q3-2025 | $0 | $42.94M ▼ | $-48.51M ▼ | 0% | $-0.92 ▼ | $-41.19M ▲ |
| Q2-2025 | $0 | $45.81M | $-42.27M | 0% | $-0.91 | $-45.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $309.16M ▲ | $339.93M ▲ | $322.93M ▲ | $17M ▼ |
| Q1-2026 | $191.47M ▲ | $215.5M ▼ | $174.72M ▲ | $40.79M ▼ |
| Q4-2025 | $187.65M ▼ | $250.77M ▼ | $155.38M ▲ | $95.39M ▼ |
| Q3-2025 | $253.2M ▲ | $275.99M ▲ | $130.87M ▲ | $145.13M ▲ |
| Q2-2025 | $135.78M | $160.83M | $26.84M | $133.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-49.48M ▲ | $-32.68M ▲ | $8.52M ▼ | $151.77M ▲ | $126.36M ▲ | $-32.7M ▲ |
| Q1-2026 | $-60.1M ▼ | $-54.5M ▼ | $21.26M ▲ | $23.21M ▲ | $-7.31M ▲ | $-54.79M ▼ |
| Q4-2025 | $-52.23M ▼ | $-40.36M ▼ | $-3.33M ▼ | $4.66M ▼ | $-35.67M ▼ | $-40.01M ▼ |
| Q3-2025 | $-48.51M ▼ | $-32.68M ▲ | $8.52M ▼ | $151.77M ▲ | $126.36M ▲ | $-32.81M ▲ |
| Q2-2025 | $-42.27M | $-39.64M | $48.67M | $295K | $9.73M | $-39.75M |
CEO
Benjamin L. Palleiko
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2016-11-22 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Showing Top 3 of 105
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Needham
Buy
HC Wainwright & Co.
Buy
Jones Trading
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:6.73M
Value:$102.55M
TANG CAPITAL MANAGEMENT LLC
Shares:5.04M
Value:$76.84M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:5.04M
Value:$76.81M
Summary
Showing Top 3 of 172